Yuanhuacine Is a Potent and Selective Inhibitor of the Basal-Like 2 Subtype of Triple Negative Breast Cancer with Immunogenic Potential

SIMPLE SUMMARY: Most breast cancers express the estrogen, progesterone, and/or HER2 receptors and patients are treated with inhibitors targeting these receptors. Triple negative breast cancers (TNBCs) lack these receptors and thus patients with TNBC do not benefit from existing targeted therapies. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Fermaintt, Charles S., Peramuna, Thilini, Cai, Shengxin, Takahashi-Ruiz, Leila, Essif, Jacob Nathaniel, Grant, Corena V., O’Keefe, Barry R., Mooberry, Susan L., Cichewicz, Robert H., Risinger, April L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201195/
https://www.ncbi.nlm.nih.gov/pubmed/34200174
http://dx.doi.org/10.3390/cancers13112834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201195/
https://www.ncbi.nlm.nih.gov/pubmed/34200174
http://dx.doi.org/10.3390/cancers13112834

Ejemplares similares